Nek7 conformational flexibility and inhibitor binding probed through protein engineering of the R-spine.
kinases
protein engineering
small molecules
Journal
The Biochemical journal
ISSN: 1470-8728
Titre abrégé: Biochem J
Pays: England
ID NLM: 2984726R
Informations de publication
Date de publication:
30 04 2020
30 04 2020
Historique:
received:
29
02
2020
revised:
02
04
2020
accepted:
03
04
2020
pubmed:
4
4
2020
medline:
15
12
2020
entrez:
4
4
2020
Statut:
ppublish
Résumé
Nek7 is a serine/threonine-protein kinase required for proper spindle formation and cytokinesis. Elevated Nek7 levels have been observed in several cancers, and inhibition of Nek7 might provide a route to the development of cancer therapeutics. To date, no selective and potent Nek7 inhibitors have been identified. Nek7 crystal structures exhibit an improperly formed regulatory-spine (R-spine), characteristic of an inactive kinase. We reasoned that the preference of Nek7 to crystallise in this inactive conformation might hinder attempts to capture Nek7 in complex with Type I inhibitors. Here, we have introduced aromatic residues into the R-spine of Nek7 with the aim to stabilise the active conformation of the kinase through R-spine stacking. The strong R-spine mutant Nek7SRS retained catalytic activity and was crystallised in complex with compound 51, an ATP-competitive inhibitor of Nek2 and Nek7. Subsequently, we obtained the same crystal form for wild-type Nek7WT in apo form and bound to compound 51. The R-spines of the three well-ordered Nek7WT molecules exhibit variable conformations while the R-spines of the Nek7SRS molecules all have the same, partially stacked configuration. Compound 51 bound to Nek2 and Nek7 in similar modes, but differences in the precise orientation of a substituent highlights features that could be exploited in designing inhibitors that are selective for particular Nek family members. Although the SRS mutations are not required to obtain a Nek7-inhibitor structure, we conclude that it is a useful strategy for restraining the conformation of a kinase in order to promote crystallogenesis.
Identifiants
pubmed: 32242624
pii: 222565
doi: 10.1042/BCJ20200128
pmc: PMC7200626
doi:
Substances chimiques
Enzyme Inhibitors
0
NEK2 protein, human
EC 2.7.11.1
NEK7 protein, human
EC 2.7.11.1
NIMA-Related Kinases
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1525-1539Subventions
Organisme : Medical Research Council
ID : MR/L017032/2
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C24461/A10285
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C24461/A13231
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L017032/1
Pays : United Kingdom
Informations de copyright
© 2020 The Author(s).
Références
Sci Rep. 2019 Dec 24;9(1):19790
pubmed: 31875044
Biochim Biophys Acta. 2015 Oct;1854(10 Pt B):1586-94
pubmed: 25936518
Front Cell Dev Biol. 2017 Dec 01;5:102
pubmed: 29250521
Elife. 2014 May 27;3:e02667
pubmed: 24867643
Acta Crystallogr D Biol Crystallogr. 2013 Jul;69(Pt 7):1204-14
pubmed: 23793146
J Proteome Res. 2014 Sep 5;13(9):4074-90
pubmed: 25093993
J Biol Chem. 2016 Jan 1;291(1):103-9
pubmed: 26553871
EMBO J. 2018 Apr 13;37(8):
pubmed: 29510984
J Appl Crystallogr. 2007 Aug 1;40(Pt 4):658-674
pubmed: 19461840
Biochim Biophys Acta. 2010 Mar;1804(3):440-4
pubmed: 19879387
Acta Crystallogr D Biol Crystallogr. 2011 Apr;67(Pt 4):235-42
pubmed: 21460441
Nat Commun. 2015 Nov 02;6:8771
pubmed: 26522158
J Biol Chem. 2007 Mar 2;282(9):6833-42
pubmed: 17197699
J Cell Sci. 2011 Nov 15;124(Pt 22):3760-70
pubmed: 22100915
Acta Crystallogr D Biol Crystallogr. 2011 Apr;67(Pt 4):355-67
pubmed: 21460454
PLoS One. 2017 Aug 2;12(8):e0181585
pubmed: 28767711
Mol Cell. 2009 Nov 25;36(4):560-70
pubmed: 19941817
Mol Cell Biol. 2009 Jul;29(14):3975-90
pubmed: 19414596
Mol Cell. 2017 Mar 2;65(5):818-831.e5
pubmed: 28216227
Protein Sci. 2009 Oct;18(10):2016-26
pubmed: 19610074
Sci Signal. 2019 Aug 13;12(594):
pubmed: 31409757
J Cell Sci. 2020 May 11;133(9):
pubmed: 32184261
Molecules. 2015 Jan 13;20(1):1176-91
pubmed: 25591119
J Med Chem. 2010 Nov 11;53(21):7682-98
pubmed: 20936789
Nature. 2019 Jun;570(7761):338-343
pubmed: 31189953
Oncotarget. 2017 Mar 21;8(12):19089-19124
pubmed: 27833088
J Mol Biol. 2009 Feb 20;386(2):476-85
pubmed: 19124027
FEBS J. 2017 Sep;284(18):2947-2954
pubmed: 28342286
Sci Signal. 2013 Jul 02;6(282):ra54
pubmed: 23821772
J Med Chem. 2011 Jun 23;54(12):4133-46
pubmed: 21627121
Cell Cycle. 2015;14(4):656-67
pubmed: 25664600
J Cell Sci. 2012 Oct 1;125(Pt 19):4423-33
pubmed: 23132929
Nat Chem Biol. 2017 Apr;13(4):402-408
pubmed: 28166210
J Med Chem. 2012 Apr 12;55(7):3228-41
pubmed: 22404346
Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32
pubmed: 15572765
Medchemcomm. 2017 Dec 8;9(1):44-66
pubmed: 30108900
Nat Chem Biol. 2015 Jul;11(7):496-503
pubmed: 26030730
Acta Crystallogr D Biol Crystallogr. 2002 Nov;58(Pt 11):1948-54
pubmed: 12393927
Mol Biol Cell. 2017 Jul 15;28(15):2123-2134
pubmed: 28539406
Nat Immunol. 2016 Mar;17(3):250-8
pubmed: 26642356
Acta Crystallogr D Biol Crystallogr. 2011 Apr;67(Pt 4):271-81
pubmed: 21460445
Mol Cell Biol. 2015 Jan;35(1):264-76
pubmed: 25348715
J Med Chem. 2011 Mar 24;54(6):1626-39
pubmed: 21366329
Open Biol. 2012 Nov;2(11):120136
pubmed: 23226601
Nat Chem Biol. 2010 Mar;6(3):166-169
pubmed: 20154661
Acta Crystallogr D Biol Crystallogr. 2008 Sep;64(Pt 9):909-18
pubmed: 18703838
Acta Crystallogr D Struct Biol. 2018 Feb 1;74(Pt 2):85-97
pubmed: 29533234
Nature. 2016 Feb 18;530(7590):354-7
pubmed: 26814970